Universal (US:UVV) Thenewswireยท2025-09-04 23:00Company Overview - Universal Ibogaine Inc. (UI) is a life sciences company focused on transforming addiction treatment using medicalized ibogaine, specifically targeting opioid use disorder through a planned clinical trial in Canada [4] - The company is also developing a holistic addiction treatment protocol at its Kelburn Recovery Centre, aimed at revolutionizing addiction treatment and improving the lives of affected individuals and families [4] Clinical Trial Announcement - UI intends to file a Clinical Trial Application (CTA) with Health Canada within 90 days to investigate ibogaine as a treatment for opioid use disorder [1] - The company has secured a reliable supply of pharmaceutical-grade ibogaine, produced in compliance with Good Manufacturing Practice (GMP) standards, ensuring quality and safety for the clinical trial [2] Leadership Statement - CEO Nick Karos emphasized the company's commitment to advancing innovative addiction therapies and expressed confidence in conducting rigorous clinical studies focused on patient safety and therapeutic effectiveness [3]